Haleon (NYSE:HLN) Stock Rating Upgraded by BNP Paribas Exane

Haleon (NYSE:HLN) was upgraded by BNP Paribas Exane from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday,Finviz reports. The brokerage currently has a $13.40 price target on the stock. BNP Paribas Exane’s target price would indicate a potential upside of 20.07% from the stock’s current price.

HLN has been the subject of several other research reports. HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley raised Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Wall Street Zen cut shares of Haleon from a “buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Haleon presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Up 0.9%

Shares of NYSE HLN opened at $11.16 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $50.30 billion, a price-to-earnings ratio of 32.82, a PEG ratio of 2.82 and a beta of 0.24. The firm’s fifty day moving average is $10.32 and its 200 day moving average is $9.92. Haleon has a 52 week low of $8.25 and a 52 week high of $11.35.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, equities research analysts expect that Haleon will post 0.43 earnings per share for the current year.

Hedge Funds Weigh In On Haleon

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in Haleon by 67.5% in the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock valued at $146,232,000 after buying an additional 6,175,835 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Haleon during the 1st quarter worth about $58,870,000. Point72 Asset Management L.P. acquired a new stake in shares of Haleon during the 4th quarter worth about $45,110,000. Raymond James Financial Inc. purchased a new stake in Haleon during the fourth quarter worth approximately $42,193,000. Finally, FMR LLC boosted its holdings in Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company’s stock valued at $1,038,217,000 after purchasing an additional 3,909,545 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.